Blood Res.  2016 Dec;51(4):285-287. 10.5045/br.2016.51.4.285.

Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma

• Cho MS
• Kim JY
• Jung SY
• Ahn SY
• Song GY
• Yang DH

• KMID: 2364322
• DOI: http://doi.org/10.5045/br.2016.51.4.285

Abstract

No abstract available.

MeSH Terms

Bendamustine Hydrochloride*
Cytarabine*
Drug Therapy*
Lymphoma*
Bendamustine Hydrochloride
Cytarabine

Figure

• 

  Fig. 1 (A) Gadolinium-enhanced, T1-weighted magnetic resonance imaging shows mild thickening and enhancement of the left optic nerve. (B) The optic nerve thickening was resolved after three cycles of R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) chemotherapy.

Reference

1. Phillips EH, Fox CP, Cwynarski K. Primary CNS lymphoma. Curr Hematol Malig Rep. 2014; 9:243–253. PMID: 24969265.

2. Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008; 49(Suppl 1):43–51. PMID: 18821432.

3. Iwamoto FM, DeAngelis LM. An update on primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2006; 20:1267–1285. PMID: 17113462.

4. Jahnke K, Thiel E, Martus P, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006; 80:159–165. PMID: 16699873.

5. Citterio G, Reni M, Ferreri AJ. Present and future treatment options for primary CNS lymphoma. Expert Opin Pharmacother. 2015; 16:2569–2579. PMID: 26371872.

6. Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol. 2003; 70:219–224. PMID: 12656744.

7. Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013; 122:2318–2330. PMID: 23963042.

8. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011; 76:929–930. PMID: 21383331.

9. Birnbaum T, Stadler EA, von Baumgarten L, Straube A. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol. 2012; 109:285–291. PMID: 22570142.

10. Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014; 83:235–239. PMID: 24928128.

11. Chamberlain MC, Johnston SK. Salvage therapy with single agent bendamustine for recurrent glioblastoma. J Neurooncol. 2011; 105:523–530. PMID: 21626071.

12. Zulkowski K, Kath R, Semrau R, Merkle K, Höffken K. Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol. 2002; 128:111–113. PMID: 11862482.

13. Chamberlain MC. Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. J Neurooncol. 2014; 118:155–162. PMID: 24584709.

14. Visco C, Finotto S, Pomponi F, et al. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/ refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. Am J Hematol. 2013; 88:289–293. PMID: 23450436.

15. Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013; 31:1442–1449. PMID: 23401442.